Drug Database
Back to search

Iceland· IS-EU/1/21/1532/001-002

Kesimpta

A ofatumumab product containing ofatumumabum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 10 of our 19 countries.

ATC L04AG12

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedKesimptaATCL04AG12REGISTER NO.IS-EU/1/21/1532/001-0…PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ofatumumabum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ofatumumab is registered in 10 of 19 countries.

Countries holding a registration under ATC L04AG12 (ofatumumab), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose
Search ofatumumab products by name

Ofatumumab · ATC L04AG12

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Ofatumumabum INN
Manufacturer
Novartis Europharm Limited*
Country
Iceland (IS)
ATC code
L04AG12
ATC class
Ofatumumab
Defined daily dose
0.67 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    031172
    0,4 ml x1 áfpen
    ISK 234338

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

70 interactions on record for ofatumumab.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ofatumumab against other medicinesHow interaction checks work

Ofatumumab · interactions on record

70 records

  • 29 severe
  • 41 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ofatumumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ofatumumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Kesimpta
  • Norway · Kesimpta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9c227434-8b0b-4dde-be04-654797c213a9
GET /v1/drugs/9c227434-8b0b-4dde-be04-654797c213a9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn í áfylltri sprautu",
  "source": "lyfjastofnun",
  "atc_raw": "L04AG12",
  "marketed": false,
  "strength": "20 mg",
  "ma_number": "EU/1/21/1532/001-002",
  "substance": "Ofatumumabum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "44281"
}
API referenceMCP serverPlans

See everything about ofatumumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console